Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene ...

Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene ...

The average one-year price target for Allogene Therapeutics (NasdaqGS:ALLO) has been revised to $8.83 / share. This is an increase of 16.66% from the prior estimate of $7.57 dated April 12, 2026. The ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb. The biotech had been enrolling patients in ...

Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026SOUTH SAN FRANCISCO, Calif., April ...

Shares of Allogene Therapeutics fell Tuesday after the company said it intends to raise up to $201.3 million through a public offering of its shares to fund clinical trials and research. The company's ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

During the last three months, 7 analysts shared their evaluations of Allogene Therapeutics (NASDAQ:ALLO), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

The decline in stock price can be attributed to the strategic changes in Allogene’s pipeline, announced at the start of this year. This delayed management’s plans to bring cema-cel, its lead pipeline ...

By Sneha S K April 13 (Reuters) - Allogene Therapeutics said on Monday that interim data from a mid-stage study showed its experimental off-the-shelf CAR-T therapy reduced the risk of cancer relapse ...